Physician profile
Stephen Gegick
NPI 1245405992
$7,747.67
in general payments reported to CMS, 2019-2025
13 companies · $3,985 in 2025
The $3,985 reported for 2025 was more than what 92% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $136 · 2021: $274 · 2022: $757 · 2023: $2,214 · 2024: $259 · 2025: $3,985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $2,120 · Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $2,119.67 |
| Food and Beverage | $1,839.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,996.79 | 2022-2025 | Da Vinci Surgical System |
| Pulmonx Corporation | $1,369.38 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Glaxosmithkline, LLC. | $1,093.44 | 2021-2024 | Nucala, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $646.95 | 2019-2025 | Tezspire, Fasenra |
| Noah Medical Corporation | $150.00 | 2025 | Galaxy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.05 | 2022-2023 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Abiomed | $135.97 | 2020 | |
| Genentech USA, INC. | $78.85 | 2022-2023 | Xolair |
| Mylan Specialty L.P. | $44.25 | 2022-2023 | Yupelri |
| Masimo Corporation | $28.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.85 | 2022 | |
| Phadia US INC. | $15.19 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Gegick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.